This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): LB84451
Description: GS 9450 is an oral, once-daily pan-caspase inhibitor. Caspases are cellular proteases involved in processes such as apoptosis (cell death) and inflammation. By inhibiting various caspases, it may be possible to slow or stop the progression of fibrosis in the liver for patients with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH), as well as potentially in other fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).
Deal Structure: In November 2007, Gilead Sciences and LG Life Sciences announced that the companies entered into an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases. The agreement grants Gilead commercialization rights to LGLS caspase inhibitors, including GS 9450 (LB84451).
Under the terms of the agreement, Gilead will pay LGLS a $20 million upfront license payment and royalties on net sales. LGLS also could earn up to $182 million in payments based upon the achievement of certain development, regulatory and commercial milestones. Gileads license is worldwide, with the exception of Korea, China and India where LGLS has retained rights. LGLS also has the worldwide right to develop and commercialize caspase inhibitors for ophthalmic and topical uses.
Partners: LG Life Sciences Ltd.
GS 9450 News
Pink Sheet STAT-C Agents In Development For Hepatitis C
Additional information available to subscribers only: